Prolonged clinical remission of type 1 diabetes sustained by calcifediol and low-dose basal insulin: a case report.

Abstract

Herein, we describe an unusually prolonged duration (31 months) of the clinical remission phase in a 22-year-old Italian man with new-onset type 1 diabetes. Shortly after the disease diagnosis, the patient was treated with calcifediol (also known as 25-hydroxyvitamin D3 or calcidiol), coupled with low-dose basal insulin, to correct hypovitaminosis D and to exploit the anti-inflammatory and immunomodulatory properties of vitamin D. During the follow-up period, the patient retained a substantial residual β-cell function and remained within the clinical remission phase, as evidenced by an insulin dose-adjusted glycated hemoglobin value <9. At 24 months, we detected a peculiar immunoregulatory profile of peripheral blood cells, which may explain the prolonged duration of the clinical remission sustained by calcifediol as add-on treatment to insulin.

• Authors: Marco Infante, Laura Vitiello, Andrea Fabbri, Camillo Ricordi, Nathalia Padilla, Francesca Pacifici, Pasquale Di Perna, Marina Passeri, David Della-Morte, Massimiliano Caprio, Luigi Uccioli
• Journal: Immunotherapy (Immunotherapy) Vol. 15 Issue 13 Pg. 1009-1019 (09 2023) ISSN: 1750-7448 [Electronic] England
• PMID: 37401348 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Calcifediol
• Vitamin D
• Insulin

Topics

• Male
• Humans
• Young Adult
• Adult
• Calcifediol (therapeutic use)
• Diabetes Mellitus, Type 1 (drug therapy)
• Vitamin D (therapeutic use)
• Insulin (therapeutic use)
• Vitamin D Deficiency